Suppr超能文献

醋酸甲地孕酮治疗艾滋病相关厌食和恶病质的随机试验。

Randomized trials of megestrol acetate for AIDS-associated anorexia and cachexia.

作者信息

Von Roenn J H

机构信息

Department of Internal Medicine, Northwestern University, Chicago, IL 60611.

出版信息

Oncology. 1994 Oct;51 Suppl 1:19-24. doi: 10.1159/000227411.

Abstract

Involuntary weight loss is a frequent complication of acquired immune deficiency syndrome (AIDS) and ultimately affects the majority of patients. The deleterious effects of weight loss on immune function and the physical and psychological sequelae of severe weight loss are well recognized. Megestrol acetate induces appetite stimulation and nonfluid weight gain in patients with advanced hormone nonresponsive cancers. In a pilot study, megestrol acetate produced nonfluid weight gain in patients with AIDS. Two double-blind randomized placebo-controlled trials of megestrol acetate for the treatment of AIDS-related anorexia and cachexia have shown improvements in body weight with treatment. In a multicenter trial reported by Flynn et al. at the 7th International Conference on AIDS (1992), 65 patients with AIDS and weight loss of > 10% of ideal body weight were randomized to placebo or megestrol acetate 800 mg/day. Megestrol acetate-treated patients had a significantly greater mean maximum weight gain (p = 0.027) and appetite stimulation (p = 0.021) than did placebo-treated patients. In a second, larger randomized placebo-controlled trial, 271 patients with AIDS, anorexia and cachexia were randomized to receive placebo or multiple doses of megestrol acetate at 100, 400 or 800 mg/day for 12 weeks. A maximum weight gain of at least 5 lb (2.25 kg) was observed in 64.2% of patients in the 800-mg megestrol acetate group compared with 21.4% in the placebo group (p < 0.0001). Mean maximum weight change from baseline to last evaluation was +8.3 lb in the 800-mg group and -1.1 lb in the placebo group (p < 0.001). Mean change in lean body mass from baseline to last evaluation was +2.5 lb in the 800-mg group versus -1.7 lb in the placebo group (p < 0.001). A significant improvement in appetite was seen in patients receiving 800 mg megestrol acetate compared with patients receiving placebo. No significant toxicity was observed with megestrol acetate therapy. Megestrol acetate is an effective treatment for some patients with AIDS-related anorexia and cachexia.

摘要

体重减轻是获得性免疫缺陷综合征(AIDS)常见的并发症,最终会影响大多数患者。体重减轻对免疫功能的有害影响以及严重体重减轻的生理和心理后遗症已得到充分认识。醋酸甲地孕酮可刺激晚期激素无反应性癌症患者的食欲并增加非体液性体重。在一项初步研究中,醋酸甲地孕酮使艾滋病患者体重增加。两项关于醋酸甲地孕酮治疗艾滋病相关厌食和恶病质的双盲随机安慰剂对照试验表明,治疗后体重有所改善。在弗林等人于第七届国际艾滋病大会(1992年)报告的一项多中心试验中,65例艾滋病患者且体重减轻超过理想体重10%的患者被随机分为安慰剂组或醋酸甲地孕酮800毫克/天组。与安慰剂治疗组相比,醋酸甲地孕酮治疗组患者的平均最大体重增加显著更大(p = 0.027),食欲刺激也更明显(p = 0.021)。在第二项更大规模的随机安慰剂对照试验中,271例艾滋病、厌食和恶病质患者被随机分为接受安慰剂组或多剂量醋酸甲地孕酮组,剂量分别为100毫克/天、400毫克/天或800毫克/天,为期12周。醋酸甲地孕酮800毫克组64.2%的患者观察到最大体重增加至少5磅(2.25千克),而安慰剂组为21.4%(p < 0.0001)。从基线到最后评估的平均最大体重变化,800毫克组为 +8.3磅,安慰剂组为 -1.1磅(p < 0.001)。从基线到最后评估,800毫克组瘦体重的平均变化为 +2.5磅,安慰剂组为 -1.7磅(p < 0.001)。与接受安慰剂的患者相比,接受800毫克醋酸甲地孕酮的患者食欲有显著改善。醋酸甲地孕酮治疗未观察到明显毒性。醋酸甲地孕酮是治疗一些艾滋病相关厌食和恶病质患者的有效方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验